| INTRODUCTION
Chronic rhinosinusitis (CRS) is a disease that is defined as inflammation of the nose and paranasal sinuses of at least 12 weeks of duration. CRS is one of the most common chronic diseases in the United States, which affects more than 10 million Americans and greatly impairs quality of life in affected patients. [1] [2] [3] [4] CRS is a heterogeneous disease and is frequently divided into 2 groups based on the presence or absence of nasal polyps (NPs): CRS with NPs (CRSwNP) and CRS without NPs (CRSsNP). Inflammatory patterns in these 2 diseases are different and also show heterogeneity. 5, 6 Pathologically, CRSwNP tissue often displays intense eosinophilic infiltration and a Th2-biased cytokine profile, especially in western countries. 7 It is well known that severe asthma shows high comorbidity with CRSwNP. 8 Furthermore, patients with CRSwNP often require repeated surgical intervention, despite the use of oral and/or topical corticosteroids. New medical approaches that can effectively shrink or eliminate NPs are clearly needed.
NPs usually present around the middle nasal meatus or paranasal sinuses as oedematous masses. Histologically, NPs consist of intense oedematous stroma and the formation of pseudocyst filled with plasma proteins accompanied by infiltration of inflammatory cells. 9 Although plasma exudation from capillaries occurs as a result of profound inflammation, the precise mechanisms of retention of extravascular plasma proteins in NP submucosa have not been fully elucidated. A previous report from our laboratory demonstrated excessive fibrin deposition, and low levels of d-dimer, a fibrin degradation product, in NPs, suggesting that fibrinolysis is impaired in NPs. 10 Profound fibrin deposition may mediate the retention of exuded plasma proteins and the formation of intense oedema in NP tissue. Activation of the coagulation cascade and deposition of fibrin are consequences of inflammation for host defence and may confine infections and support repair processes. 11 However, dysregulation of the coagulation cascade is involved in the aetiology of many diseases in which excessive fibrin deposition occurs, including rheumatoid arthritis, adult respiratory distress syndrome and severe asthma. [12] [13] [14] Ordinarily, fibrin degradation is mediated by plasmin, which is generated through cleavage of plasminogen by urokinase plasminogen activator (u-PA) and/or tissue plasminogen activator (t-PA). Our previous study demonstrated profound down-regulation of t-PA expression in NPs, but not u-PA. 10 The data showed that t-PA was most prominently observed in epithelial and glandular cells in normal uncinate tissue (UT), but expression was lost in NP epithelium. Tissue plasminogen activator converts plasminogen to plasmin, which is then responsible for the degradation of cross-linked of fibrin. 
| Cell viability assay
One hundred lL of NHBE cells (1 9 10 6 cells/well) was seeded in a collagen-coated 96-well tissue culture plates. Cells were cultured in BEGM without hydrocortisone for at least 24 hours before stimulation. Cells were exposed to concentrations of SCFA used in the activation studies, and viability was assayed as described below. A solution of 1% Triton X-100 (Sigma-Aldrich) was used as a positive control. Before stimulation, the medium was replaced, and NHBE cells were incubated with SCFAs. After 24 hours, 20 lL of MTS reagent (Promega, Madison, WI, USA) was added. The absorbance was measured after 2 hours at 490 nm using the Spectra max Gemini EM (Molecular Device, Sunnyvale, CA).
| pH measurement
The pH of medium containing SCFAs was measured using Accumet 
| Statistical analysis
All data are presented as the mean AE SEM, unless otherwise mentioned. The data from culture experiments were analysed using the paired Student's t test. Differences between the groups were analysed with the Kruskal-Wallis ANOVA with Dunnett post hoc testing and a Mann-Whitney U test. In all cases, P < .05 was considered to be statistically significant. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA) software.
3 | RESULTS
| Epithelial cells expressed both GPR41 and GPR43 in sinonasal tissue
To assess the expression of GPR41 and GPR43 in sinonasal tissues and in NP tissues, we performed IHC analysis of surgical specimens from uncinate tissue (UT) of control and NPs from CRSwNP subjects ( Figure 1 ). Expression of both GPR41 and GPR43 was observed in sinonasal epithelial cells as well as resident and infiltrating cells within the lamina propria.
3.2 | GPR41 and GPR43 mRNA expressions were up-regulated in nasal polyp tissue
Next, we wanted to know the expression levels of both GPR41 and GPR43 in sinonasal tissue. The mRNA from whole tissue extracts was analysed to compare the expression levels of both GPR41 and GPR43. As shown in Figure 2A ,B, the expression of both GPR41 and T A B L E 1 Characteristics of the subjects GPR43 mRNA was ten-to 100-fold higher in NPs compared to control UT samples (GPR41; P < .001, GPR 43: P < .0001). As IHC analysis showed that both GPR41 and GPR43 were expressed in epithelial cells, we evaluated expression of both genes in fresh nasal cells collected by scraping. As with whole tissue extracts, the expression of both GPR41 and GPR43 was significantly higher (two to tenfold) in nasal scraping-derived epithelial cells from NPs compared to normal UT epithelial scrapings (GPR41; P < .05, GPR 43: P < .001, Figure 2C ,D).
| SCFAs induced t-PA from NHBE cells
We stimulated cultured submerged NHBE cells with SCFAs in vitro. As shown in Figure 3A , propionic acid, butyric acid and valeric acid strongly induced t-PA expression in a concentrationdependent manner, whereas acetic acid only weakly induced t-PA and hexanoic acid did not induce t-PA. The maximal concentrations of SCFAs to significantly induce t-PA in NHBE cells were 10 mmol/L for acetic acid (P < .05), 1 mmol/L for propionic acid (P < .05), 0.5 mmol/L for butyric acid (P < .05) and 1 mmol/L for valeric acid (P < .05); none of these concentrations induced harmful effects on the viability of NHBE cells ( Figure S1 ). We measured t-PA protein levels in the supernatants from SCFA stimulated NHBE cells by ELISA. A 48-hour stimulation with SCFAs induced t-PA protein release from NHBE cells into the supernatant ( Figure 3B ). The levels of t-PA released into the supernatant by stimulation with propionic acid (P < .001), butyric acid (P < .05) and valeric acid (P < .05) were significantly higher (three-to fivefold) than levels in supernatants of non-stimulated NHBE cells. In the presence of SCFA in the medium, there were no significant pH changes ( Figure S2 ).
| Epithelial-derived t-PA was in the active form
To assess whether released t-PA was in the active form, we measured t-PA activity with a commercially available t-PA activity kit. As propionic acid was the strongest inducer of t-PA in NHBE cells, we used propionic acid in further experiments. We found that a significant amount of t-PA released from non-stimulated NHBE cells was in the active form. Supernatants from propionic acid stimulated NHBE cells showed significantly higher t-PA activity compared to non-stimulated NHBE cells and the increase in activity was proportionally similar to the increased level of t-PA mRNA (approx. threefold) ( Figure 3C ). These results indicate that at least a proportion of the t-PA released into the supernatant by both unstimulated and stimulated epithelial cells is in the active form.
| SCFA-induced t-PA is secreted by NHBE cells onto both apical and basolateral surfaces
Most of the fibrin deposition that has been described in NP is found in the lamina propria within NPs. 10 To test whether t-PA induced by SCFAs is released at the site of cross-linked fibrin, we tested whether the release was basolateral or apical. To clarify this point, NHBE cells were cultured in collagen-coated transwells.
Cell lysates, basolateral media and apical supernatants were all collected after 48 hours of stimulation with 10 mmol/L propionic acid, and t-PA was measured by ELISA. Propionic acid significantly enhanced t-PA protein levels found in cell lysates as well as in both apical and basolateral media ( Figure 3D ). The results demonstrate that 78.5% of the total amount of t-PA produced by propionic acid stimulated NHBE was released and the remainder was retained in the cells. Although 66.8% of the released t-PA was found in the apical supernatants, a substantial amount (33.2%) was released to the basolateral side. To clarify whether the administration of propionate affects TEER, which might affect the passage of t-PA between the apical and basolateral layers, we also measured TEER. We found that the administration of propionate did not have any significant effect on TEER ( Figure S3 ). These results indicate that induction of t-PA by SCFAs in vivo might be expected to increase the amounts of t-PA found within the tissue both above and below the basement membrane. by Western blot analysis after transfection (P < .05, Figure 5A ,B).
Although the genes were not completely suppressed, the reduction of either gene alone was sufficient to partially inhibit t-PA induction by propionic acid ( Figure 5C,D) . The combination of siRNA against both receptors leads to nearly complete suppression of t-PA expression, as shown in Figure 5E , supporting an involvement of both GPR41 and GPR43 in SCFA-mediated induction of t-PA in NHBE cells.
| SCFAs induced t-PA from PNECs
Induction of t-PA by SCFA or synthetic agonists for their receptors, Induction of the t-PA gene and t-PA activity is regulated by several mechanisms. 43 The regulation of t-PA gene transcription has thus far been investigated in a variety of cell types. Retinoic acid, butyric acid and statins are known to increase t-PA gene expression in endothelial cells, but the precise mechanism is not well understood. 18, 43, 44 In the present study, we demonstrate that SCFAs can induce t-PA in NHBE cells and PNECs without any harmful effects on cell viability. Among several SCFAs, propionic acid tended to be the most effective agonist inducing t-PA in both NHBE cells and PNECs. Although the SCFAs induced t-PA at concentrations in the mmol/L level, these levels are similar to levels found in vivo and are in the same range as reports in other cell types. 33 This level of potency may restrict the activation mechanism of both GPR41 and GPR43 by SCFAs to specific locations in the body. We showed that a significant amount of t-PA released from propionic acid stimulated NHBE cells was in the active form, and t-PA from transwell cultured NHBE cells was released both apically and basolaterally, indicating that some t-PA released from airway epithelial cells should reach the submucosal layer and effect fibrin degradation in the tissue.
SCFAs are generated in part by bacterial fermentation of dietary fibres by gut microbiota. SCFAs are produced at concentrations of 100 mmol/L in the gut lumen, and the major components are acetic acid (C2), propionic acid (C3) and butyric acid (C4). 45 Previous studies have highlighted the variety of functions of SCFAs in inflammation, carcinogenesis, metabolism and allergy. [22] [23] [24] [25] [26] [27] [28] There is interest in SCFA receptors as attractive pharmaceutical targets having a broad range of potential therapeutic applications. 46 Thus, it is important to clarify the signalling partners associated with SCFA beneficial effects.
We showed that the receptors, GPR41 and GPR43, are present in epithelial cells of both normal uncinate tissue and in NPs. This is the first report that these GPRs exist in the upper airway epithelium. GPCRs constitute the largest class of cell surface receptors, consisting of Ga, Gb and Gc subunits. GPCR is classified into 4 families according to their a subunit: Gi, Gs, G12/13 and Gq. 47 The Gq family activates phospholipase and consists of 4 members:
Gq, G11, G14 and G15/16 and their respective a subunits are thus Gaq, Ga11 and Ga14. 48 On the other hand, the Ga15/16, and Gs and Gi families regulate adenylyl cyclase activity. 43 PTX inhibits the a subunit of Gi proteins by locking the a subunits in a GDP-bound inactive state. Although GPR41 and GPR43 display 43% amino acid identity, they have different affinities for SCFAs. 49 The rank order of potency for GPR41 is propionic acid~butyric acid~valeric acid > acetic acid, whereas the corresponding rank for GPR43 is acetic acid~propionic acid > butyric acid > valeric acid. 30, 31 These potency rank orders for both GPRs are consistent with our results that propionic acid was, for the most part, the strongest inducer of t-PA in NHBE, and the response was inhibited by both Gai/o and Gaq/11 inhibitors. We pretreated NHBE cells with both PTX and YM-254890 to test the combined inhibitory effect on t-PA induction. The result showed greater inhibition than either drug alone but revealed some residual t-PA that was not suppressed (Figure 4C ), indicating either that the drugs did not completely block their targets or that other mechanisms might be present. Other potential mechanisms by which SCFAs could affect the cells might be via effects mediated by a transporter or pursuant to direct passage of the SCFAs across the cell membrane.
Once inside the cell, SCFAs might affect signal transduction or transcriptional events, as reported elsewhere. 26, 45 It has been reported that SCFAs can act as histone deacetylase inhibitors (HDACi), 26 and HDACi can also enhance t-PA induction in endothelial cells. We therefore tested whether trichostatin A, a broad HDACi, induces t-PA in NHBE cells. The results showed that trichostatin A increased t-PA expression ( Figure S6 ). We also Another group also reported that high fibre diet or SCFA administration modified the development of allergic airway disease. This report provided evidence for a role of diet and acetic acid in the development of airway disease in humans. 28 As Th2 cytokines are elevated in NPs and IL-13 can down-regulate t-PA, SCFAs might also indirectly be able to decrease the size of NPs by dampening type 2 inflammation in addition to inducing release of t-PA. We found that expression of both GPR41 and GPR43 mRNA was elevated in NPs in surgical samples (Figure 2A,B) , which might reflect the infiltration of GPR41 or GPR43 expressing inflammatory cells in NPs, as well as increased expression by epithelial cells. Although further studies are required, we speculate that the administration of SCFAs might produce beneficial effects for treatment of NPs by more than one mechanism.
In summary, we showed that SCFAs, especially propionic acid, butyric acid and valeric acid, induced the expression and release of t-PA by airway epithelial cells, and that released t-PA was in the active form. We also found that the SCFA receptors GPR41 and GPR43 are expressed by nasal epithelial cells and can mediate the induction of t-PA following stimulation with SCFAs. Our results indicate that allosteric agonists for GPR41 and GPR43, including SCFAs, might be worthy of consideration as a new strategy for treatment of NPs.
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